Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2016, Article ID 2637010, 8 pages
http://dx.doi.org/10.1155/2016/2637010
Research Article

Elevated Serum Levels of the Antiapoptotic Protein Decoy-Receptor 3 Are Associated with Advanced Liver Disease

1Academic Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens 11527, Greece
2First Department of Pathology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens 11527, Greece
3Infectious Diseases Research Laboratory, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens 11527, Greece

Received 3 February 2016; Revised 28 June 2016; Accepted 17 July 2016

Academic Editor: Aldo J. Montano-Loza

Copyright © 2016 Giorgos Bamias et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Forner, J. M. Llovet, and J. Bruix, “Hepatocellular carcinoma,” The Lancet, vol. 379, no. 9822, pp. 1245–1255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Szabo and D. Lippai, “Molecular hepatic carcinogenesis: impact of inflammation,” Digestive Diseases, vol. 30, no. 3, pp. 243–248, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. W.-W. Lin and S.-L. Hsieh, “Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer,” Biochemical Pharmacology, vol. 81, no. 7, pp. 838–847, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Zhan, Y. Patskovsky, Q. Yan et al., “Decoy strategies: the structure of TL1A:DcR3 complex,” Structure, vol. 19, no. 2, pp. 162–171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Bamias, K. Evangelou, T. Vergou et al., “Upregulation and nuclear localization of TNF-like Cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions,” Experimental Dermatology, vol. 20, no. 9, pp. 725–731, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Bai, B. Connolly, M. L. Metzker et al., “Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 3, pp. 1230–1235, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Wu, B. Han, H. Sheng et al., “Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients,” International Journal of Cancer, vol. 105, no. 5, pp. 724–732, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Ge, A. J. Sanders, L. Ye, Y. Wang, and W. G. Jiang, “Expression of death decoy receptor-3 (DcR3) in human breast cancer and its functional effects on breast cancer cells in vitro,” Journal of Experimental Therapeutics and Oncology, vol. 9, no. 2, pp. 109–118, 2011. View at Google Scholar · View at Scopus
  9. J. Chen, L. Zhang, and S. Kim, “Quantification and detection of DcR3, a decoy receptor in TNFR family,” Journal of Immunological Methods, vol. 285, no. 1, pp. 63–70, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Bamias, G. Kaltsa, S. I. Siakavellas et al., “Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn's disease,” Digestive and Liver Disease, vol. 44, no. 1, pp. 30–36, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Bamias, G. Kaltsa, S. I. Siakavellas et al., “High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis,” Clinical Immunology, vol. 137, no. 2, pp. 242–249, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Bamias, S. I. Siakavellas, K. S. Stamatelopoulos, E. Chryssochoou, C. Papamichael, and P. P. Sfikakis, “Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis,” Clinical Immunology, vol. 129, no. 2, pp. 249–255, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Kim, L. Mi, and L. Zhang, “Specific elevation of DcR3 in sera of sepsis patients and its potential role as a clinically important biomarker of sepsis,” Diagnostic Microbiology and Infectious Disease, vol. 73, no. 4, pp. 312–317, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Yang, G. Chen, Y. Dang, and D. Luo, “Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients,” Upsala Journal of Medical Sciences, vol. 115, no. 4, pp. 232–237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Chen and D. Luo, “Expression of decoy receptor 3 in liver tissue microarrays,” National Medical Journal of India, vol. 21, no. 6, pp. 275–278, 2008. View at Google Scholar · View at Scopus
  16. C. Chen, C. Zhang, G. Zhuang et al., “Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC) development,” Cancer Investigation, vol. 26, no. 10, pp. 965–974, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer, “EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma,” Journal of Hepatology, vol. 56, no. 4, pp. 908–943, 2012. View at Publisher · View at Google Scholar
  18. K. Ishak, A. Baptista, L. Bianchi et al., “Histological grading and staging of chronic hepatitis,” Journal of Hepatology, vol. 22, no. 6, pp. 696–699, 1995. View at Publisher · View at Google Scholar
  19. S.-C. Weng, K.-H. Shu, M.-J. Wu et al., “Expression of decoy receptor 3 in kidneys is associated with allograft survival after kidney transplant rejection,” Scientific Reports, vol. 5, article 12769, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Kim, V. Kotoula, P. Hytiroglou, D. Zardavas, and L. Zhang, “Significance of increased expression of decoy receptor 3 in chronic liver disease,” Digestive and Liver Disease, vol. 41, no. 8, pp. 591–598, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Aiba, K. Harada, A. Komori et al., “Systemic and local expression levels of TNF-like ligand 1A and its decoy receptor 3 are increased in primary biliary cirrhosis,” Liver International, vol. 34, no. 5, pp. 679–688, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Hou, P. Xu, X. Lou et al., “Serum decoy receptor 3 is a useful predictor for the active status of chronic hepatitis b in hepatitis b e antigen-negative patients,” Tohoku Journal of Experimental Medicine, vol. 230, no. 4, pp. 227–232, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. J. P. Connor and M. Felder, “Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance,” Gynecologic Oncology, vol. 111, no. 2, pp. 330–335, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. R. M. Gill and J. S. Hunt, “Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHT-mediated apoptosis,” American Journal of Pathology, vol. 165, no. 1, pp. 309–317, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Han and J. Wu, “DcR3 protects islet β cells from apoptosis through modulating Adcyap1 and Bank1 expression,” The Journal of Immunology, vol. 183, no. 12, pp. 8157–8166, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. W. Li, C. Zhang, C. Chen, and G. Zhuang, “Correlation between expression of DcR3 on tumor cells and sensitivity to FasL,” Cellular & Molecular Immunology, vol. 4, no. 6, pp. 455–460, 2007. View at Google Scholar · View at Scopus
  27. V. J. Wroblewski, D. R. Witcher, G. W. Becker et al., “Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT,” Biochemical Pharmacology, vol. 65, no. 4, pp. 657–667, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. H.-W. Shen, S.-L. Gao, Y.-L. Wu, and S.-Y. Peng, “Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis,” World Journal of Gastroenterology, vol. 11, no. 38, pp. 5926–5930, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. C. Chang, T. L. Hsu, H. H. Lin et al., “Modulation of macrophage differentiation and activation by decoy receptor 3,” Journal of Leukocyte Biology, vol. 75, pp. 486–494, 2004. View at Google Scholar
  30. S.-K. Tai, H.-C. Chang, K.-L. Lan et al., “Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages,” Journal of Immunology, vol. 188, no. 5, pp. 2464–2471, 2012. View at Publisher · View at Google Scholar · View at Scopus